Conference News: Growing Trends in SGLT2i Prescriptions for Heart Failure Patients
Study Highlights SGLT2i Prescription Trends
On November 26, 2024 (HealthDay News), research presented at the American Heart Association Scientific Sessions 2024 discusses increasing prescription rates of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for patients suffering from heart failure with a left ventricular ejection fraction (LVEF) greater than 40 percent. According to the findings published in JAMA Cardiology, the study tracked prescription trends from 2021 to 2023.
Key Findings from the Research
- From 158,849 eligible heart failure patients, 13.9 percent received SGLT2i prescriptions at discharge.
- Quarterly prescription rates escalated from 4.2 percent in September 2021 to 23.5 percent in September 2023.
- Patients with mildly reduced LVEF (41-49 percent) were prescribed SGLT2i more frequently than those with preserved LVEF (≥50 percent): 18.5 percent versus 13.0 percent.
- Disparities in SGLT2i prescriptions varied significantly across hospitals, affecting treatment consistency.
Implications for Heart Failure Management
The results indicate a transformative shift in managing heart failure, specifically amongst patients showing LVEF >40 percent. The increased SGLT2i prescription may improve outcomes, yet it underscores the need for uniform treatment protocols across healthcare facilities.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.